Myrexis, Inc. (OTCPK: MYRX)
Health Care · Biotechnology · US
$0.00
-27.27% today · +166.7% 1Y
Myrexis, Inc. (OTCPK: MYRX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $27.58K and employs 1 people.
Over the last twelve months the share price has gained 166.7%, trading between 0.00 and 0.01.
Tweenvest scores Myrexis, Inc. across four factors: quality 29/100. Its strongest factor is quality.
MYRX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $27.58K
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.39
- Dividend yield
- —
- Beta (5Y)
- 3.18
- 52-week high
- $0.01
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 34.48M
- Employees
- 1
- Next earnings
- —
About Myrexis, Inc.
Myrexis, Inc. dedicates its efforts to identifying, evaluating, and financially backing ventures within the life sciences sector. The company, which now operates under the name Myrexis, Inc., was previously known as Myriad Pharmaceuticals, Inc. until its rebranding took place in July 2010. Its main corporate offices are situated in New York, New York.
- ISIN
- US62856H1077
- Listed since
- Jun 12, 2009
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $265.55 | +0.22% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $441.32 | +0.45% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.34 | +0.15% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $549.06 | +0.18% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $826.41 | -0.91% |
| argenx SEENXTBR: ARGX | $65.85B | €864.20 | -4.19% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $137.91 | -4.94% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.